Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Colchicine  COVID-19 treatment studies for Colchicine  C19 studies: Colchicine  Colchicine   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 67% Improvement Relative Risk Recovery 63% Gorial et al. Colchicine for COVID-19 RCT LATE TREATMENT Is late treatment with colchicine beneficial for COVID-19? RCT 160 patients in Iraq Improved recovery with colchicine (p=0.001) Gorial et al., Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.103593 Favors colchicine Favors control
Randomized controlled trial of colchicine add on to the standard therapy in moderate and severe corona virus Disease-19 infection
Gorial et al., Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.103593
Gorial et al., Randomized controlled trial of colchicine add on to the standard therapy in moderate and severe corona virus.., Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.103593
Apr 2022   Source   PDF  
  All Studies   Meta
RCT with 80 colchicine and 80 control patients, showing improved recovery with treatment. SOC included vitamin C, vitamin D, and zinc.
risk of death, 66.7% lower, RR 0.33, p = 0.62, treatment 1 of 80 (1.2%), control 3 of 80 (3.8%), NNT 40.
risk of no recovery, 62.8% lower, HR 0.37, p < 0.001, treatment 80, control 80, inverted to make HR<1 favor treatment, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Gorial et al., 12 Apr 2022, Randomized Controlled Trial, Iraq, peer-reviewed, 6 authors, dosage 1mg days 1-7, 0.5mg days 8-15.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperColchicineAll
Abstract: Journal Pre-proof Randomized controlled trial of colchicine add on to the standard therapy in moderate and severe corona virus Disease-19 infection Faiq I. Gorial, Mohammed Fauzi Maulood, Ahmed S. Abdulamir, Ahmed Sameer Alnuaimi, Manal K. abdulrrazaq, Fadil Agla Bonyan PII: S2049-0801(22)00353-3 DOI: Reference: AMSU 103593 To appear in: Annals of Medicine and Surgery Received Date: 18 February 2022 Revised Date: 1 April 2022 Accepted Date: 2 April 2022 Please cite this article as: Gorial FI, Maulood MF, Abdulamir AS, Alnuaimi AS, abdulrrazaq MK, Bonyan FA, Randomized controlled trial of colchicine add on to the standard therapy in moderate and severe corona virus Disease-19 infection, Annals of Medicine and Surgery (2022), doi: j.amsu.2022.103593. This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2022 Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. 1 A Randomized Controlled Trial of Colchicine add on to the Standard Therapy in Moderate and Severe Corona Virus Disease-19 Infection Faiq I. Gorial 1, Mohammed Fauzi Maulood2 , , Ahmed S. Abdulamir 3 , Ahmed Sameer Alnuaimi 4, Manal K. abdulrrazaq 5, Fadil Agla Bonyan 6 ro of 1, 5 College of Medicine, University of Baghdad, Bab Al-Muadham, Baghdad, Iraq 2 Alkarkh Hospital, Alatefiya, Baghdad, Iraq 3 College of Medicine, Alnahrain University, Alkadymia, Baghdad, Iraq 4 Primary Health Care Corporation, Department Of Clinical Research, Aldoha, Qatar 6 Emergency physician, Director of EMS of Iraq, Emergency medical department, Baghdad Teaching Hospital Corresponding author email: Jo ur na lP re -p Running title: Colchicine as Add-on Therapy to the Standard of Care Measures in COVID-19 Therapy Table 1: Baseline characteristics of the study groups. Study groups Intervention (Colchicine add on) + moderate Control + Severe Control + disease disease moderate disease N % N % N % Intervention (Colchicine add on) + Severe disease N % Age group (years) 18-39 40-59 60+ Total 8 14 18 40 20.0 35.0 45.0 100.0 Smoking habit Non-smoker Current smoker Ex-smoker Total 25 10 5 40 62.5 25.0 12.5 100.0 Comorbidities Hypertension Diabetes Mellitus Ischemic Heart Disease Asthma Cancer Stroke Others Any..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop